Navigation Links
Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
Date:10/6/2011

NEW YORK, Oct. 6, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets

http://www.reportlinker.com/p0286297/Women's-Health-Therapeutics-Analysis-and-Market-Forecasts-to-2016---High-Unmet-Need-will-Drive-the-Uptake-of-Novel-Drugs-in-the-Menopause-and-Osteoporosis-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets

Summary

GBI Research's report, "Women's Health Therapeutics Market to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in Menopause and Osteoporosis", provides in-depth analysis of unmet needs, drivers and barriers that impact the global women's health market. The report analyzes the markets for women's health in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The Scope of this report includes:

- Annualized market data for the women's health market from 2001 to 2009, forecast forward to 2016.

- Analysis of the leading therapeutic segments, including osteoporosis, hormone therapy for menopause, endometriosis, women's infertility and polycistic ovarian syndrome.

- Analysis of the women's health market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.

- Market characterization of the women's health market, including market size, annual cost of therapy, sales volume and treatment usage patterns.

- Key drivers and barriers that have a significant impact on the market.

- Coverage of pipeline molecules in various phases of drug development.

- Competitive benchmarking of leading companies. The key companies studied in this report are Merck, Pfizer, Johnson & Johnson, Teva Pharmaceuticals and Bayer-Schering Pharma.

- Key M&A activities, licensing agreements, that have taken place in 2009 in the global blood disorders market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.

- Develop key strategic initiatives by understanding the key focus areas of leading companies.

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 7

2 Global WH Disorder Therapeutics Market:Introduction 10

2.1 GBI Research Report Guidance 10

3 Global WH Disorder Therapeutics Market: Market Characterization 11

3.1 Introduction 11

3.2 Revenue Forecasts for the Global WH Disorder Therapeutics Market 12

3.2.1 Sales Value 12

3.2.2 Annual Cost of Therapy 13

3.2.3 Treatment Usage Patterns 14

3.2.4 Generics' Share in the Global WH Disorder Therapeutics Market 20

4 Global WH Disorder Therapeutics Market: Therapeutic Landscape 21

4.1 Global Menopause Therapeutics Market 21

4.1.1 Introduction 21

4.1.2 Sales Value 21

4.1.3 Annual Cost of Therapy 23

4.1.4 Treatment Usage Patterns 24

4.1.5 Drivers and Barriers for the Menopause Therapeutics Market 30

4.1.6 Market share by Geography 31

4.1.7 Product Analysis 33

4.2 Global Endometriosis Therapeutics Market 38

4.2.1 Introduction 38

4.2.2 Sales Value 39

4.2.3 Annual Cost of Therapy 40

4.2.4 Treatment Usage Patterns 41

4.2.5 Drivers and Barriers for the Endometriosis Therapeutics Market 46

4.2.6 Market share by Geography 47

4.2.7 Product Analysis 48

4.3 Global Postmenopausal Osteoporosis (PMO) Market 51

4.3.1 Introduction 51

4.3.2 Sales Value 52

4.3.3 Annual Cost of Therapy 53

4.3.4 Treatment Usage Patterns 54

4.3.5 Drivers and Barriers for the Menopause Therapeutics Market 60

4.3.6 Market Share by Geography 61

4.3.7 Product Analysis 63

5 Global WH Disorder Therapeutics Market: Geographical Landscape 68

5.1 Geographical Break-up 68

5.2 The US 71

5.2.1 Sales Value 71

5.2.2 Annual Cost of Therapy 72

5.2.3 Treatment Usage Patterns 73

5.3 Top Five Markets in Europe 78

5.3.1 Sales Value 78

5.3.2 Annual Cost of Therapy 79

5.3.3 Treatment Usage Patterns 80

5.4 Japan 85

5.4.1 Sales Value 85

5.4.2 Annual Cost of Therapy 86

5.4.3 Treatment Usage Patterns 87

6 Global WH Disorder Therapeutics Market: Pipeline Analysis 92

6.1 Introduction 92

6.1.1 Research and Development Pipeline – Menopause 94

6.1.2 Research and Development Pipeline – Endometriosis 96

6.1.3 Research and Development Pipeline - Postmenopausal Osteoporosis 98

6.2 Profiles of Key Late-Stage Drugs in the WH disorder Therapeutics Market 101

6.2.1 Aprela (Bazedoxifene/Conjugated Estrogen) 101

6.2.2 Pristiq (Desvenlaxafine, DVS-233) 102

6.2.3 Visanne 103

6.2.4 Elagolix (NBI-56418) 103

6.2.5 Odanacatib (MK-0822) 104

6.2.6 Viviant (Bazedoxifene) 105

7 Global WH Disorder Therapeutics Market: Competitive Landscape 106

7.1 Market Share Analysis: Women's Health 106

7.2 Competitive Profiling 108

7.2.1 Pfizer Inc 108

7.3 Eli Lilly and Company 109

7.4 Merck & Co. 110

7.5 Procter & Gamble Company 112

7.6 Hoffmann-La Roche Ltd. 114

8 Global WH Disorder Therapeutics Market: Strategic Consolidations 117

8.1 Mergers and Acquisitions 117

8.1.1 Overview 117

8.1.2 Ferring Pharmaceuticals Acquires Global Rights to LYSTEDA from Xanodyne Pharmaceuticals in May 2010 121

8.1.3 BioSante Acquires Elestrin Royalty from Azur Pharma in March 2010 121

8.1.4 Teva-KOWA Pharma Acquires Majority Stake in Taisho Pharmaceutical in February 2010 121

8.1.5 Sciele Pharma Acquires Addrenex Pharmaceuticals in November 2009 121

8.1.6 Warner Chilcott Acquires Prescription Drug Business of Procter & Gamble in October 2009 121

8.1.7 BioSante Pharmaceuticals Merges with Cell Genesys in October 2009 122

8.1.8 Hisamitsu Pharmaceutical Completes Acquisition Of Noven Pharmaceuticals in August 2009 122

8.1.9 Pfizer Acquires Wyeth in January 2009 122

8.1.10 Par Pharmaceuticals Acquires Assets Of Calcitonin & A Manufacturing Facility From MDRNA in April 2009 122

8.2 R&D Licensing Agreements 123

8.2.1 Deals by Indication 123

8.2.2 Deals by Phase 124

8.2.3 Deals by Geography 125

9 Global WH Disorder Therapeutics Market: Appendix 126

9.1 Market Definitions 126

9.2 Abbreviations 126

9.3 Coverage 128

9.3.1 Secondary Research 128

9.3.2 Primary Research 128

9.3.3 Forecasts 129

9.3.4 Expert Panel Validation 131

9.4 Contact Us 131

9.5 Disclaimer 131

9.6 Sources 132

1.1 List of Tables

Table 1: WH Disorder Therapeutics Market, Global, Sales Value ($bn), 2001–2009 12

Table 2: WH Disorder Therapeutics Market, Global, Sales Value ($bn), 2009–2016 13

Table 3: WH Disorder Therapeutics Market, Global, Annual Cost of Therapy ($), 2001–2009 13

Table 4: WH Disorder Therapeutics Market, Global, Annual Cost of Therapy ($), 2009–2016 14

Table 5: WH Disorder Therapeutics Market, Global, Treatment Usage Patterns (in millions), 2001–2009 15

Table 6: WH Disorder Therapeutics Market, Global, Treatment Usage Patterns (in millions), 2009–2016 15

Table 7: WH Disorder Therapeutics Market, Global, Menopause Sales Value ($bn), 2001–2009 22

Table 8: WH Disorder Therapeutics Market, Global, Menopause Sales Value ($bn), 2009–2016 22

Table 9: WH Disorder Therapeutics Market, Global, Menopause Annual Cost of Therapy ($), 2001–2009 23

Table 10: WH Disorder Therapeutics Market, Global, Menopause Annual Cost of Therapy ($), 2009–2016 23

Table 11: WH Disorder Therapeutics Market, Global, Menopause Treatment Usage Patterns (in millions), 2001–2009 25

Table 12: WH Disorder Therapeutics Market, Global, Menopause Treatment Usage Patterns (in millions), 2009–2016 25

Table 13: WH Disorder Therapeutics Market, Global, Endometriosis Sales Value ($bn), 2001–2009 39

Table 14: WH Disorder Therapeutics Market, Global, Endometriosis Sales Value ($bn), 2009–2016 39

Table 15: WH Disorder Therapeutics Market, Global, Endometriosis Annual Cost of Therapy ($), 2001–2009 40

Table 16: WH Disorder Therapeutics Market, Global, Endometriosis Annual Cost of Therapy ($), 2009–2016 40

Table 17: WH Disorder Therapeutics Market, Global, Endometriosis Treatment Usage Patterns (in millions), 2001–2009 41

Table 18: WH Disorder Therapeutics Market, Global, Endometriosis Treatment Usage Patterns (in millions), 2009–2016 42

Table 19: WH Disorder Therapeutics Market, Global, PMO Sales Value ($bn), 2001–2009 52

Table 20: WH Disorder Therapeutics Market, Global, PMO Sales Value ($bn), 2009–2016 52

Table 21: WH Disorder Therapeutics Market, Global, PMO Annual Cost of Therapy ($), 2001–2009 53

Table 22: WH Disorder Therapeutics Market, Global, PMO Annual Cost of Therapy ($), 2009–2016 54

Table 23: WH Disorder Therapeutics Market, Global, PMO Treatment Usage Patterns (in millions), 2001–2009 55

Table 24: WH Disorder Therapeutics Market, Global, PMO Treatment Usage Patterns (in millions), 2009–2016 55

Table 25: WH Disorder Therapeutics Market, Global, Sales Value by Geography ($bn), 2001–2009 69

Table 26: WH Disorder Therapeutics Market, Global, Sales Value by Geography ($bn), 2009–2016 69

Table 27: WH Disorder Therapeutics Market, The US, Sales Value ($bn), 2001–2009 71

Table 28: WH Disorder Therapeutics Market, The US, Sales Value ($bn), 2009–2016 71

Table 29: WH Disorder Therapeutics Market, The US, Annual Cost of Therapy ($), 2001–2009 72

Table 30: WH Disorder Therapeutics Market, The US, Annual Cost of Therapy ($), 2009–2016 72

Table 31: WH Disorder Therapeutics Market, The US, Treatment Usage Patterns (in millions), 2001–2009 73

Table 32: WH Disorder Therapeutics Market, The US, Treatment Usage Patterns (in millions), 2009–2016 74

Table 33: WH Disorder Therapeutics Market, Top Five Markets in Europe, Sales Value ($bn), 2001–2009 78

Table 34: WH Disorder Therapeutics Market, Top Five Markets in Europe, Sales Value ($bn), 2009–2016 78

Table 35: WH Disorder Therapeutics Market, Top Five Markets in Europe, Annual Cost of Therapy ($), 2001–2009 79

Table 36: WH Disorder Therapeutics Market, Top Five Markets in Europe, Annual Cost of Therapy ($), 2009–2016 79

Table 37: WH Disorder Therapeutics Market, Top Five Markets in Europe, Treatment Usage Pattern (in millions), 2001–2009 80

Table 38: WH Disorder Therapeutics Market, Top Five Markets in Europe, Treatment Usage Pattern (in millions), 2009–2016 81

Table 39: WH Disorder Therapeutics Market, Japan, Sales Value ($bn), 2001–2009 85

Table 40: WH Disorder Therapeutics Market, Japan, Sales Value ($bn), 2009–2016 85

Table 41: WH Disorder Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001–2009 86

Table 42: WH Disorder Therapeutics Market, Japan, Annual Cost of Therapy ($), 2009–2016 86

Table 43: WH Disorder Therapeutics Market, Japan, Treatment Usage Pattern (in millions), 2001–2009 87

Table 44: WH Disorder Therapeutics Market, Japan, Treatment Usage Pattern (in millions), 2009–2016 88

Table 45: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market, Phase III Pipeline, August 2010 95

Table 46: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market, Phase II Pipeline, August 2010 95

Table 47: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market, Phase I Pipeline, August 2010 95

Table 48: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market, Preclinical Pipeline, August 2010 96

Table 49: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Endometriosis Market, Phase III and Regulatory Filing, August 2010 97

Table 50: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Endometriosis Market, Phase II Pipeline, August 2010 97

Table 51: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Endometriosis Market, Phase I Pipeline, August 2010 97

Table 52: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Endometriosis Market, Preclinical Pipeline, August 2010 97

Table 53: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market, Phase III and Regulatory Filing, August 2010 99

Table 54: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market, Phase II Pipeline, August 2010 99

Table 55: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market, Phase I Pipeline, August 2010 99

Table 56: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market, Preclinical Pipeline, August 2010 100

Table 57: WH Disorder Therapeutics Market, Global, Major M&A Deals, 2009–2010 120

1.2 List of Figures

Figure 1: Women's Health Market, Global, Drivers and Restraints, 2009 11

Figure 2: WH Disorder Therapeutics Market, Global, Sales Value ($bn), 2001–2016 12

Figure 3: WH Disorder Therapeutics Market, Global, Annual Cost of Therapy ($), 2001–2016 13

Figure 4: WH Disorder Therapeutics Market, Global, Therapeutic Usage Patterns, 2001–2016 14

Figure 5: WH Disorder Therapeutics Market, Global, Diseased Population (in millions), 2001–2016 16

Figure 6: WH Disorder Therapeutics Market, Global, Treatment Seeking Population (in millions), 2001–2016 17

Figure 7: WH Disorder Therapeutics Market, Global, Diagnosed Population (in millions), 2001–2016 18

Figure 8: WH Disorder Therapeutics Market, Global, Prescription Population (in millions), 2001–2016 19

Figure 9: WH Disorder Therapeutics Market, Global, Branded v/s Generic Drugs, $bn, 2001–2016 20

Figure 10: WH Disorder Therapeutics Market, Global, Menopause Sales Value ($bn), 2001–2016 22

Figure 11: WH Disorder Therapeutics Market, Global, Menopause Annual Cost of Therapy ($), 2001–2016 23

Figure 12: WH Disorder Therapeutics Market, Global, Menopause Treatment Usage Patterns (million), 2001–2016 24

Figure 13: WH Disorder Therapeutics Market, Global, Menopause Diseased Population (in millions), 2001–2016 26

Figure 14: WH Disorder Therapeutics Market, Global, Menopause Treatment Seeking Population (in millions), 2001–2016 27

Figure 15: WH Disorder Therapeutics Market, Global, Menopause Diagnosis Population (in millions), 2001–2016 28

Figure 16: WH Disorder Therapeutics Market, Global, Menopause Prescription Population (in millions), 2001–2016 29

Figure 17: WH Disorder Therapeutics Market, Global, Menopause, Market Segmentation by Geography, 2009 and 2016 31

Figure 18: WH Disorder Therapeutics Market, Global, Menopause, Market Segmentation by Geography, 2001 - 2016 32

Figure 19: WH Disorder Therapeutics Market, Global, Endometriosis Sales Value ($bn), 2001–2016 39

Figure 20: WH Disorder Therapeutics Market, Global, Endometriosis Annual Cost of Therapy ($), 2001–2016 40

Figure 21: WH Disorder Therapeutics Market, Global, Endometriosis Treatment Usage Patterns (million), 2001–2016 41

Figure 22: WH Disorder Therapeutics Market, Global, Endometriosis Diseased Population (in millions), 2001–2016 42

Figure 23: WH Disorder Therapeutics Market, Global, Endometriosis Treatment Seeking Population (in millions), 2001–2016 43

Figure 24: WH Disorder Therapeutics Market, Global, Endometriosis Diagnosis Population (in millions), 2001–2016 44

Figure 25: WH Disorder Therapeutics Market, Global, Endometriosis Prescription Population (in millions), 2001–2016 45

Figure 26: WH Disorder Therapeutics Market, Global, Endometriosis, Market Segmentation by Geography, 2009 and 2016 47

Figure 27: WH Disorder Therapeutics Market, Global, Endometriosis, Market Segmentation by Geography, 2001 - 2016 48

Figure 28: WH Disorder Therapeutics Market, Global, PMO Sales Value ($bn), 2001–2016 52

Figure 29: WH Disorder Therapeutics Market, Global, PMO Annual Cost of Therapy ($), 2001–2016 53

Figure 30: WH Disorder Therapeutics Market, Global, PMO Treatment Usage Patterns (in millions), 2001–2016 54

Figure 31: WH Disorder Therapeutics Market, Global, PMO Diseased Population (in millions), 2001–2016 56

Figure 32: WH Disorder Therapeutics Market, Global, PMO Treatment Seeking Population (in millions), 2001–2016 57

Figure 33: WH Disorder Therapeutics Market, Global, PMO Diagnosis Population (in millions), 2001–2016 58

Figure 34: WH Disorder Therapeutics Market, Global, PMO Prescription Population (in millions), 2001–2016 59

Figure 35: WH Disorder Therapeutics Market, Global, PMO, Market Segmentation by Geography, 2009 and 2016 61

Figure 36: WH Disorder Therapeutics Market, Global, PMO, Market Segmentation by Geography, 2009–2016 62

Figure 37: WH Disorder Therapeutics Market, Global, Market Share by Geography, 2009 and 2016 68

Figure 38: WH Disorder Therapeutics Market, Global, Sales Value by Geography ($bn), 2001–2016 69

Figure 39: WH Disorder Therapeutics Market, Global, Geography Benchmarking, 2009 and 2016 70

Figure 40: WH Disorder Therapeutics Market, US, Sales Value ($bn), 2001–2016 71

Figure 41: WH Disorder Therapeutics Market, The US, Annual Cost of Therapy ($), 2001–2016 72

Figure 42: WH Disorder Therapeutics Market, The US, Treatment Usage Patterns (in millions), 2001–2016 73

Figure 43: WH Disorder Therapeutics Market, The US, Diseased Population (in millions), 2001–2016 74

Figure 44: WH Disorder Therapeutics Market, The US, Treatment Seeking Population (in millions), 2001–2016 75

Figure 45: WH Disorder Therapeutics Market, The US, Diagnosis Population (in millions), 2001–2016 76

Figure 46: WH Disorder Therapeutics Market, The US, Prescription Population (in millions), 2001–2016 77

Figure 47: WH Disorder Therapeutics Market, Top Five Markets in Europe, Sales Value ($bn), 2001–2016 78

Figure 48: WH Disorder Therapeutics Market, Top Five Markets in Europe, Annual Cost of Therapy ($), 2001–2016 79

Figure 49: WH Disorder Therapeutics Market, Top Five Markets in Europe, Treatment Usage Patterns (in millions), 2001–2016 80

Figure 50: WH Disorder Therapeutics Market, Top Five Markets in Europe, Diseased Population (in millions), 2001–2016 81

Figure 51: WH Disorder Therapeutics Market, Top Five Markets in Europe, Treatment Seeking Population (in millions), 2001–2016 82

Figure 52: WH Disorder Therapeutics Market, Top Five Markets in Europe, Diagnosis Population (in millions), 2001–2016 83

Figure 53: WH Disorder Therapeutics Market, Top Five Markets in Europe, Prescription Population (in millions), 2001–2016 84

Figure 54: WH Disorder Therapeutics Market, Japan, Sales Value ($m), 2001–2016 85

Figure 55: WH Disorder Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001–2016 86

Figure 56: WH Disorder Therapeutics Market, Japan, Treatment Usage Pattern (in millions), 2001–2016 87

Figure 57: WH Disorder Therapeutics Market, Japan, Diseased Population (in millions), 2001–2016 88

Figure 58: WH Disorder Therapeutics Market, Japan, Treatment Seeking Population (in millions), 2001–2016 89

Figure 59: WH Disorder Therapeutics Market, Japan, Diagnosed Population (in millions), 2001–2016 90

Figure 60: WH Disorder Therapeutics Market, Japan, Prescription Population (in millions), 2001–2016 91

Figure 61: WH Disorder Therapeutics Market, Global, R&D Pipeline by Indication (%), August 2010 92

Figure 62: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase (%), August 2010 93

Figure 63: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market (%), August 2010 94

Figure 64: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in the Endometriosis Therapeutics Market (%), August 2010 96

Figure 65: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market (%), August 2010 98

Figure 66: WH Disorder Therapeutics Market, Global, Market Share of Top Manufacturers (%), 2009 106

Figure 67: WH Disorder Therapeutics Market, Global, Revenue of Top Five Players ($m), 2009 107

Figure 68: WH Disorder Therapeutics Market, Global, Average value, Revenue of Top Five Players ($m), 2009 107

Figure 69: WH Disorder Therapeutics Market, SWOT Analysis, Pfizer, 2009 109

Figure 70: WH Disorder Therapeutics Market, SWOT Analysis, Eli Lilly, 2009 110

Figure 71: WH Disorder Therapeutics Market, SWOT Analysis, Merck, 2009 111

Figure 72: WH Disorder Therapeutics Market, SWOT Analysis, Procter & Gamble, 2009 113

Figure 73: WH Disorder Therapeutics Market, SWOT Analysis, Hoffman-La Roche, 2009 116

Figure 74: WH Disorder Therapeutics Market, Global, M&A Deals by Indication (%), 2004-2010 117

Figure 75: WH Disorder Therapeutics Market, Global, M&A Deals by Deal Type (%), 2009 118

Figure 76: WH Disorder Therapeutics Market, Global, M&A Deals by Deal Value (%), 2009 119

Figure 77: WH Disorder Therapeutics Market, Global, Major Licensing Agreements By Indication (%), 2004–2010 123

Figure 78: WH Disorder Therapeutics Market, Global, Major Licensing Agreements By Phase (%), 2004–2010 124

Figure 79: WH Disorder Therapeutics Market, Global, Major Licensing Agreements By Geography (%), 2009–2010 125

Figure 80: GBI Research Market Forecasting Model, 2010 130

Companies mentioned

Eli Lilly and Company

Merck & Co.

Procter & Gamble Company

Hoffmann-La Roche Ltd.

Pfizer Inc

To order this report:

Pathology Industry: Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Avista Capital Partners Appoints Hakan Bjorklund as Healthcare Operating Executive
2. New Leader for CyttaConnect™ Medical Monitoring eHealth Division
3. FDA Commissioner Outlines Steps to Spur Biomedical Innovation, Improve Health of Americans
4. A New Model of Healthcare is Unveiled, Offering Seniors Control, Independence and Dignity as They Age
5. Unilife Wins Supply Contract with Nations Largest Healthcare Alliance
6. GlaxoSmithKline Donates Scientific Equipment to Advance IDRIs Global Health Mission
7. ECRI Institute Celebrates National Healthcare Resource & Materials Management Week
8. Cardinal Health to Release First-quarter Financial Results on Oct. 27
9. Craneware Supports Forward-Thinking Community Hospital Executives to Strengthen U.S. Community Healthcares Business Performance
10. Awarepoint Corporation Receives Frost & Sullivans 2011 North American RFID and RTLS Healthcare Competitive Strategy Leadership Award
11. Kaiser Foundation Hospitals and Health Plan Appoints Meg Porfido to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ZIONA, Israel , May 4, 2016 ... BVXV) announced today that BiondVax,s CEO, Dr. Ron Babecoff ... in New York City . ... 10:30am at Pioneers 2016, a conference presented by Joseph ... Palace Hotel. The BiondVax presentation that Dr. Babecoff ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Multiple Myeloma Market and ... their offering.       (Logo: ... Market and Competitive Landscape Highlights 2016, provides ... Multiple Myeloma epidemiology, Multiple Myeloma market valuations ...
(Date:5/3/2016)... May 4, 2016 Global ... pages, profiling 09 key companies and supported with ... and in-depth study on the current state of ... of the industry including definitions, classifications, applications and ... is provided for the international market including development ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... , ... The joy associated with Mother’s Day is mixed with worry and fear for new ... across the country. For the first time ever, the March of Dimes and ... their Mother’s Day beside a crib surrounded by lifesaving equipment or peering through a glass ...
(Date:5/6/2016)... ... May 06, 2016 , ... A wide variety of national pet product manufacturers, companies ... and Safety Media Showcase Wednesday, May 18 from noon to 8 p.m. at New York ... peek at new and established home, garden, outdoor and safety pet products in today’s marketplace. ...
(Date:5/6/2016)... Milford, PA (PRWEB) , ... May 06, 2016 ... ... CoolSculpting does to reduce fat areas around the body, is the most ... The survey results just released make perfect sense to cosmetic surgeon Dr. Richard ...
(Date:5/6/2016)... ... ... From May 4 to 6, EarQ and Signia co-sponsored a ... more about Signia’s technology and the successful business and marketing techniques that make EarQ ... practices succeed in this highly competitive industry,” said Ed Keller, president of EarQ. “This ...
(Date:5/6/2016)... ... May 06, 2016 , ... The International Yoga Teacher Training schoo ... the island close to the town famous for its sunsets, Oia. This all inclusive ... continue to have an amazing experience in Greece, we just can’t stay away” says ...
Breaking Medicine News(10 mins):